Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Chronic kidney disease (CKD): US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Chronic kidney disease: the short answer

The US FDA has approved five medicines covered on this page for chronic kidney disease, each for a specific group of patients: Farxiga, Jardiance, Kerendia, Ozempic and XPHOZAH 10 mg. On 17 October 2026, four of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Farxiga, Jardiance, Kerendia, Ozempic and XPHOZAH 10 mg.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is chronic kidney disease?

Chronic kidney disease (CKD) means the kidneys are damaged and cannot filter blood as they should, so waste and extra fluid can build up in the body. The kidneys also help keep the body's chemicals balanced, help control blood pressure and make hormones.[1, 2]

Diabetes and high blood pressure are the most common causes. The damage usually happens slowly over many years, and many people have no symptoms until the disease is very advanced. Blood and urine tests are the only way to know if you have kidney disease. In the United States, more than 1 in every 7 adults have CKD.[1, 2]

Treatments cannot cure kidney disease, but they may slow it. They include medicines to lower blood pressure, control blood sugar and lower cholesterol. Several newer medicines are approved in the US to reduce the risk of kidney function decline.[1, 3, 4]

Chronic kidney disease in the Gulf

A 2023 study examined the prevalence and management of hyperkalemia in patients with CKD and heart failure in the Gulf Cooperation Council countries.[5]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 4 of 5 were listed in Saudi Arabia and 4 of 5 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[6, 7]

US FDA-approved medicines for chronic kidney disease

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Farxiga (dapagliflozin)
    US FDA-approved for reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death and heart failure hospitalization in adults with CKD at risk of progression. It is a tablet, sold as Forxiga outside the US. The label says it is not recommended for polycystic kidney disease.[3]
    Current US label version: 10 July 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed as Forxiga. Abu Dhabi (DoH drug code list): listed as Forxiga. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
  • Jardiance (empagliflozin)
    US FDA-approved for reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression. It is a tablet.[8]
    Current US label version: 26 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
  • Kerendia (finerenone)
    US FDA-approved for reducing the risk of eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal heart attack and heart failure hospitalization in adults with CKD associated with type 2 diabetes. It is a tablet.[4]
    Current US label version: 21 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
  • Ozempic (semaglutide)
    US FDA-approved for reducing the risk of eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and CKD. It is a weekly injection.[9]
    Current US label version: 30 July 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, Egypt, India, Pakistan
  • XPHOZAH 10 mg (tenapanor)
    US FDA-approved for reducing serum phosphorus in adults with CKD on dialysis, as add-on therapy when phosphate binders are not enough or not tolerated. It is a tablet.[10]
    Current US label version: 27 June 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, India

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[11, 12] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for chronic kidney disease

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for chronic kidney disease?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Farxiga, Jardiance, Kerendia, Ozempic and XPHOZAH 10 mg. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Farxiga available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed as Forxiga. Abu Dhabi (Department of Health drug code list): listed as Forxiga. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Farxiga?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Are these CKD medicines available locally?

Several are. Jardiance, Kerendia and Ozempic were found in the Saudi and Abu Dhabi lists we checked, and dapagliflozin is listed as Forxiga. Ask your nephrologist and local pharmacy first.

Sources for the condition-specific answers: [6, 7]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. MedlinePlus (US National Library of Medicine): Chronic Kidney Disease
  2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): What Is Chronic Kidney Disease in Adults?
  3. DailyMed: FARXIGA (dapagliflozin) US prescribing information, label version 10 July 2026
  4. DailyMed: KERENDIA (finerenone) US prescribing information, label version 21 September 2026
  5. AlSahow A, et al. Prevalence and management of hyperkalemia in chronic kidney disease and heart failure patients in the Gulf Cooperation Council (GCC). J Clin Hypertens (Greenwich). 2023 (PubMed 36715554)
  6. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  7. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  8. DailyMed: JARDIANCE (empagliflozin) US prescribing information, label version 26 August 2026
  9. DailyMed: OZEMPIC (semaglutide) US prescribing information, label version 30 July 2026
  10. DailyMed: XPHOZAH 10 MG (tenapanor) US prescribing information, label version 27 June 2025
  11. SFDA: Special Access Program (SAP) guidance, version 1.0
  12. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp